The risk of skin rash and stomatitis with the mammalian target of rapamycin inhibitor temsirolimus: A systematic review of the literature and meta-analysis Review uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Exanthema
  • Protein Kinase Inhibitors
  • Sirolimus
  • Stomatitis

abstract

  • There is a significant risk of developing skin rash and stomatitis in cancer patients receiving temsirolimus. The risk is independent of underlying tumour. Adequate monitoring and early intervention are recommended to prevent debilitating toxicity and suboptimal dosing.

publication date

  • February 2012

Research

keywords

  • Review

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.ejca.2011.11.028

PubMed ID

  • 22206873

Additional Document Info

start page

  • 340

end page

  • 6

volume

  • 48

number

  • 3